Integrated CRISPR-based detection of HIV, tuberculosis, malaria, and resistance-associated variants
En palabras de los autores
HIV, tuberculosis (TB) and malaria are major infectious diseases that frequently co-circulate in high-burden settings, yet their diagnostic pathways remain largely disease-specific, complicating detection of coinfection and integration of antimicrobial-resistance testing. Here we developed HTM CARMEN, a highly multiplexed CRISPR-Cas13a molecular-testing framework that integrates detection of HIV-1, HIV-2, four Plasmodium species and Mycobacterium tuberculosis (Mtb) with detection of isoniazid-resistance-associated inhA and katG variants. We find that HTM CARMEN retained target selectivity and single-nucleotide discrimination across in vitro experiments and clinically relevant sample matrices, including whole blood, serum, sputum and dried blood spots. Across 20 contrived samples for each condition, the HTM panel supported detection of low-abundance targets across multiple matrices and frequently detected greater number of low-input samples as positive than qPCR under the conditions tested. In contrived P. falciparum/HIV-1 and Mtb/HIV-1 coinfections, both pathogens were simultaneously detected across a range of relative target concentrations. Using confirmed-positive clinical samples, HTM CARMEN achieved positive percent agreement of 95% for malaria (19/20), 95% for HIV-1 (19/20) and 100% for Mtb (30/30), with 100% negative percent agreement for each target in the confirmed-negative samples. Both HIV-1 and Mtb were additionally detected in all nine confirmed-positive HIV-TB coinfection specimens. These findings establish the feasibility of integrating pathogen detection, species differentiation, resistance-associated variant interrogation and coinfection detection within a programmable molecular-testing platform, providing a framework for high-throughput integrated testing in co-endemic settings.
En palabras simples Resumen con IA
Los autores desarrollaron HTM CARMEN, una prueba basada en CRISPR que detecta VIH, tuberculosis, malaria y variantes de resistencia a medicamentos en una sola plataforma. La prueba identificó correctamente el 95% de las muestras de malaria y VIH-1, y el 100% de las muestras de tuberculosis en especímenes clínicos confirmados positivos. Detectó ambos patógenos en las nueve muestras con coinfección confirmada de VIH-tuberculosis. La prueba también encontró tanto malaria como VIH, o tuberculosis y VIH, en infecciones mixtas artificiales a diferentes concentraciones. Estos resultados muestran que combinar la detección de patógenos, identificación de especies, pruebas de resistencia y detección de coinfecciones en un solo sistema es posible.
Escrito por Kimi K2.5 usando solo el abstract de arriba. Jev verificó que cada oración esté respaldada por las oraciones del abstract que cita y eliminó las que no. Pasá el cursor por una oración para ver de dónde sale.
Apareció: miércoles, 30 de septiembre. medRxiv. Preprint, todavía sin revisión por pares.